keyword
MENU ▼
Read by QxMD icon Read
search

Fampridine

keyword
https://www.readbyqxmd.com/read/29695598/preapproval-and-postapproval-evidence-on-drugs-for-multiple-sclerosis
#1
REVIEW
Chiara Gerardi, Vittorio Bertele', Silvia Rossi, Silvio Garattini, Rita Banzi
OBJECTIVE: To review the evidence supporting the European Union marketing authorization of drugs for multiple sclerosis (MS) and assess how far postmarketing research addresses information gaps at the time of approval. METHODS: Through its database, we identified drugs approved by the European Medicines Agency and gathered data on pivotal trials from the European Public Assessment Reports and corresponding publications. We searched Medline, Embase, Cochrane Library, and trial registries for postmarketing randomized controlled trials testing the drugs identified in any form of the disease...
April 25, 2018: Neurology
https://www.readbyqxmd.com/read/29552356/prolonged-release-fampridine-as-adjunct-therapy-to-active-motor-training-in-ms-patients-a-pilot-double-blind-randomized-placebo-controlled-study
#2
François Jacques, Adrian Schembri, Avi Nativ, Chantal Paquette, Pawel Kalinowski
Background: Both prolonged-release fampridine (PRF) and enabling active motor training (EAMT) are beneficial in multiple sclerosis (MS) patients. Their combined effect is, however, understudied. Objective: The objective of this paper is to determine if PRF augments the beneficial effect of EAMT in MS patients as opposed to placebo. Method: This is a pilot, randomized, placebo-controlled, double-blind 14-week study. Participants were randomly assigned to receive PRF 10 mg BID ( n  = 21) or placebo ( n  = 20)...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29464379/positive-effects-of-fampridine-on-cognition-fatigue-and-depression-in-patients-with-multiple-sclerosis-over-2-years
#3
Sarah D Broicher, Linard Filli, Olivia Geisseler, Nicole Germann, Björn Zörner, P Brugger, M Linnebank
OBJECTIVE: To assess the effects of PR-fampridine on cognitive functioning, fatigue and depression in patients with multiple sclerosis (PwMS). METHODS: Thirty-two PwMS were included in this trial. Cognitive performance was assessed in an open-label and randomized double-blind, placebo-controlled study design using a comprehensive neuropsychological test battery as well as questionnaires examining depression and fatigue. RESULTS: We found significant improvements in cognitive measures assessing alertness (tonic alertness, p = 0...
May 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29381946/efficacy-and-safety-of-9-nonoperative-regimens-for-the-treatment-of-spinal-cord-injury-a-network-meta-analysis
#4
Da-Nian Ma, Xia-Qi Zhang, Jie Ying, Zhong-Jun Chen, Li-Xin Li
OBJECTIVE: This network meta-analysis aims to compare the efficacy and safety of 9 nonoperative regimens (placebo, pregabalin, GM-1 ganglioside, venlafaxine extended-release [venlafaxine XR], fampridine, conventional over-ground training [OT], body-weight-supported treadmill training [BWSTT], robotic-assisted gait training [RAGT] + OT and body-weight-supported over-ground training [BWSOT]) in treating spinal cord injury (SCI). METHODS: Clinical controlled trials of 9 nonoperative regimens for SCI were retrieved in the electronic database...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28992626/multiple-sclerosis-and-clinical-gait-analysis-before-and-after-fampridine-a-systematic-review
#5
Magaly Lecat, Pierre Decavel, Eloi Magnin, Brigitte Lucas, Vincent Gremeaux, Yoshimasa Sagawa
BACKGROUND: Gait impairment is one of the most disabling symptoms in people with multiple sclerosis (PwMS). Fampridine, has demonstrated a positive effect on gait speed in PwMS after 14 days of treatment but the long-term effects have not yet been demonstrated. This study reviews the long-term effects of fampridine on gait in PwMS. SUMMARY: This systematic review was conducted according to the PRISMA statement. Studies were considered long term if treatment exceeded 28 days...
2017: European Neurology
https://www.readbyqxmd.com/read/28987349/corrigendum-to-high-throughput-liquid-chromatography-tandem-mass-spectrometry-method-for-simultaneous-determination-of-fampridine-paroxetine-and-quinidine-in-rat-plasma-application-to-in%C3%A2-vivo-perfusion-study-j-food-drug-anal-24-2016-866-875
#6
https://www.readbyqxmd.com/read/28911626/high-throughput-liquid-chromatography-tandem-mass-spectrometry-method-for-simultaneous-determination-of-fampridine-paroxetine-and-quinidine-in-rat-plasma-application-to-in-vivo-perfusion-study
#7
Suneetha Achanti, Raja Rajeswari Katta
A selective and high-throughput liquid chromatography-mass spectrometry method has been developed and validated for the simultaneous quantification of paroxetine, fampridine, and quinidine in rat plasma using imipramine as an internal standard. Following protein precipitation extraction, the analytes and internal standard were run on XBridge C18 column (150 mm × 4.6 mm, 5 μm) using a gradient mobile phase consisting of 5mM ammonium formate in water (pH 9.0) and acetonitrile in a flow gradience program...
October 2016: Journal of Food and Drug Analysis
https://www.readbyqxmd.com/read/28894033/author-response-monitoring-long-term-efficacy-of-fampridine-in-gait-impaired-patients-with-multiple-sclerosis
#8
Linard Filli, Björn Zörner, Tim Killeen, Michael Linnebank
No abstract text is available yet for this article.
September 12, 2017: Neurology
https://www.readbyqxmd.com/read/28894032/letter-re-monitoring-long-term-efficacy-of-fampridine-in-gait-impaired-patients-with-multiple-sclerosis
#9
Floyd A Davis
No abstract text is available yet for this article.
September 12, 2017: Neurology
https://www.readbyqxmd.com/read/28864863/fampridine-prolonged-release-a-review-in-multiple-sclerosis-patients-with-walking-disability
#10
Esther S Kim
Oral fampridine prolonged release (PR) [Fampyra®] is a lipid-soluble selective potassium channel blocker that is approved in the EU for the improvement of walking in adult multiple sclerosis (MS) patients with walking disability (expanded disability status scale score of 4-7). In clinical trials (MS-F203 and MS-F204) using an objective measure of walking improvement [the timed 25-foot walk (T25FW)], more than one-third of patients receiving fampridine PR achieved a consistent on-treatment improvement in walking speed (i...
September 2017: Drugs
https://www.readbyqxmd.com/read/28741976/fampridine-response-in-ms-patients-with-gait-impairment-in-a-real-world-setting-need-for-new-response-criteria
#11
Francisco Alejandro Rodriguez-Leal, Rocco Haase, Katja Thomas, Judith Christina Eisele, Undine Proschmann, Thorsten Schultheiss, Raimar Kern, Tjalf Ziemssen
OBJECTIVE: The primary objective of this real-world study was to describe the response to fampridine and changes of gait parameters in multiple sclerosis (MS) patients' walking disability (Expanded Disability Status Scale (EDSS): 4-7) after treatment with fampridine for 2 weeks as recommended by the European Medicines Agency (EMA) and compare it with the overall physician's judgement. METHODS: A total of 211 adult MS patients were analyzed using a multimodal gait assessment including the timed 25-foot walk test (T25FW), 2-minute walking test (2-MWT), 12-item Multiple Sclerosis Walking Scale (MSWS-12), the GAITRite electronic walkway system, and the patients' clinical global impression (CGI)...
July 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28397001/gait-ataxia-in-humans-vestibular-and-cerebellar-control-of-dynamic-stability
#12
Roman Schniepp, Ken Möhwald, Max Wuehr
During human locomotion, vestibular feedback control is fundamental for maintaining dynamic stability and adapting the gait pattern to external circumstances. Within the supraspinal locomotor network, the cerebellum represents the key site for the integration of vestibular feedback information. The cerebellum is further important for the fine-tuning and coordination of limb movements during walking. The aim of this review article is to highlight the shared structural and functional sensorimotor principles in vestibular and cerebellar locomotion control...
October 2017: Journal of Neurology
https://www.readbyqxmd.com/read/28376639/the-effect-of-symptom-controlling-medication-on-gait-outcomes-in-people-with-multiple-sclerosis-a-systematic-review
#13
Kate Behm, Prue Morgan
PURPOSE: To synthesise and critically appraise randomised controlled trials examining the effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis (MS). METHOD: The literature search examined five databases (Medline, Embase, AMED, Cochrane (CENTRAL), and CINAHL until the end of November 2016. Eligible studies included medication to address symptoms associated with MS and an objective gait outcome measure. Two reviewers independently extracted data and assessed study quality using structured data extraction forms and the PEDro scale...
April 4, 2017: Disability and Rehabilitation
https://www.readbyqxmd.com/read/28347283/healthcare-resource-use-and-costs-of-multiple-sclerosis-patients-in-germany-before-and-during-fampridine-treatment
#14
Tjalf Ziemssen, Christine Prosser, Jennifer Scarlet Haas, Andrew Lee, Sebastian Braun, Pamela Landsman-Blumberg, Angela Kempel, Erika Gleißner, Sarita Patel, Ming-Yi Huang
BACKGROUND: Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and costs of MS patients on fampridine treatment for 12 months in Germany were analyzed. METHODS: A retrospective claims database analysis was conducted including MS patients who initiated fampridine treatment (index date) between July 2011 and December 2013...
March 27, 2017: BMC Neurology
https://www.readbyqxmd.com/read/28236802/assessment-of-the-efficacy-and-safety-of-fampridine
#15
Beatriz Mejuto, Paloma Castellano, Concepción Castro, Luis Manuel López
OBJECTIVE: Assessment of the efficacy and safety of fampridine for walking improvement in adult patients with multiple sclerosis. METHOD: A descriptive retrospective study of all patients who initiated treatment with fampridine between March, 2014 and February, 2015. Efficacy was assessed through the 25-foot walk test and the 12-item walking scale for multiple sclerosis. It was reviewed whether patients had suffered any of the most frequent adverse effects described in the pivotal clinical trial...
March 1, 2017: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/28148629/monitoring-long-term-efficacy-of-fampridine-in-gait-impaired-patients-with-multiple-sclerosis
#16
RANDOMIZED CONTROLLED TRIAL
Linard Filli, Björn Zörner, Sandra Kapitza, Katja Reuter, Lilla Lörincz, David Weller, Tabea Sutter, Tim Killeen, Philipp Gruber, Jens A Petersen, Michael Weller, Michael Linnebank
OBJECTIVE: To expand upon the limited knowledge of the long-term effects of prolonged-release (PR) fampridine in patients with multiple sclerosis (PwMS) regarding safety, walking improvements, and changes in drug responsiveness. METHODS: Fifty-three PwMS who completed the FAMPKIN core study were included in this extension trial. Drug efficacy was assessed in an open-label and randomized double-blind, placebo-controlled study design with regular baseline assessments over a period of 2 years using the Timed 25-Foot Walk (T25FW), 6-Minute Walk Test (6MWT), and 12-item MS Walking Scale (MSWS-12) as outcome measures...
February 28, 2017: Neurology
https://www.readbyqxmd.com/read/28148627/fampridine-long-term-benefits-in-walking-in-multiple-sclerosis
#17
EDITORIAL
Susan E Bennett
No abstract text is available yet for this article.
February 28, 2017: Neurology
https://www.readbyqxmd.com/read/28104253/the-effect-of-fampridine-sr-on-cognitive-fatigue-in-a-randomized-double-blind-crossover-trial-in-patients-with-ms
#18
RANDOMIZED CONTROLLED TRIAL
Sarah A Morrow, Heather Rosehart, Andrew M Johnson
BACKGROUND: Cognitive fatigue (CF) is a common complaint in persons with MS (PwMS). Fampridine-SR improves ambulation, fatigue and endurance, due to enhancing action potential formation by blocking potassium channels in demyelinated axons. Thus, through this same mechanism, it is hypothesized that Fampridine-SR could improve CF. OBJECTIVE: To determine if Fampridine-SR objectively improves CF in PwMS. METHODS: Sixty PwMS of any type with CF, defined as 3 or less correct responses when comparing the last third to the first third on the Paced Auditory Serial Addition Test (PASAT), were recruited from a tertiary care MS clinic in London (ON) Canada...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28054826/experience-with-fampridine-in-clinical-practice-analysis-of-a-possible-marker-of-clinical-response
#19
Miriam Alvarez-Payero, Candelas Valeiras-Muñoz, Susana Lion-Vázquez, Guadalupe Piñeiro-Corrales, Delicias Muñoz-García, Luciana Midaglia
PURPOSE OF THE STUDY: Approximately 85% of patients with multiple sclerosis experience reduced mobility, which negatively affects quality of life. Fampridine is the first symptomatic treatment aimed at improving gait. We analyzed effectiveness and tolerance in clinical practice. We also sought a prevalent gait pattern in responders as a potential clinical response marker. MATERIAL AND METHODS: Six-month prospective study of fampridine in patients with multiple sclerosis...
March 30, 2017: International Journal of Neuroscience
https://www.readbyqxmd.com/read/27919481/effect-of-slow-release-fampridine-on-muscle-strength-rate-of-force-development-functional-capacity-and-cognitive-function-in-an-enriched-population-of-ms-patients-a-randomized-double-blind-placebo-controlled-study
#20
RANDOMIZED CONTROLLED TRIAL
H B Jensen, J L Nielsen, M Ravnborg, U Dalgas, P Aagaard, E Stenager
DESIGN: This study was conducted as a randomized, double blind, placebo-controlled parallel group trial preceded by open label enrichment phase. OBJECTIVES: The objectives of this study were 1) to examine the effect of SR-Fampridine treatment on muscle strength in terms of maximal voluntary contraction (MVC) and rate of force development (RFD) of the lower extremities and 2) to replicate previously published data on the effect of slow release-Fampridine (SR-Fampridine) on the functional capacity of the lower limbs, the upper limb and cognitive function, in persons with multiple sclerosis (pwMS)...
November 2016: Multiple Sclerosis and related Disorders
keyword
keyword
44475
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"